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ﺮﺜﻛﻷﺍﺐﺒﺴﻟﺍﻲﻫﺔﻴﻣﺰﺗﺎﻣﻭﺮﻟﺍﻰﻤﺤﻟﺍﺮﺒﺘﻌﺗﺎﻤﻨﻴﺑ،ﺔﻣﺪﻘﺘﻤﻟﺍﻥﺍﺪﻠﺒﻟﺍﻲﻓﺕﺎﻬﻣﻷﺍ
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Objectives: Congenital heart disease in pregnancy is a
leading cause of maternal death in developed countries
while rheumatic fever is the commonest cause of
valvular disease in pregnancy in developing countries.
Improvement in neonatal and paediatric cardiac sur-
gery has increased the incidence of congenital heart
disease in pregnancy worldwide. Published data
regarding heart disease in pregnancy (HDP) in KSA are
scant and relatively old. This study examines the cur-
rent status of HDP in KSA and describes the rationale
and design of the suggested plan for HDP in KSA, i.e.,
the Registry Of Saudi Heart Disease And Pregnancy
(ROSHDAP).
Methods: A systematic search was conducted through the
ProQuest MEDLINE database using the keyword
phrase “cardiovascular disease in pregnancy”. An exten-
sive literature review about heart disease in pregnancywas
performed.
Results: There are only 4 available Saudi studies of
HDP. The ROSHDAP study is expected to establish a
foundation for Saudi research in this field and will
create an extensive database that will enrich knowledge
about HDP. All Saudi women with HDP who wish to
participate are eligible for enrolment in the registry.
Five phases are planned for the registry, and data will
be collected prospectively, confidentially, and electron-
ically. The data will be transmitted from participating
centres to a central coordinating office for data man-
agement and analysis.
Conclusion: The ROSHDAP study suggested in this
article will provide contemporary data on HDP in KSA
that will promote research and encourage evidence-based
medical care of pregnant women with heart disease.y. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2016.06.004
Table 1: Comparison of outcomes of heart disease during
pregnancy in developed and developing countries.a
Variable Total Developed Developing P
value
Number of women 1321 1136 185
Baseline
F.O. Alatawi406Keywords: Cardiomyopathy; Congenital heart disease; Preg-
nancy; Rheumatic heart disease; Saudi registry
 2016 The Author.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Age, mean (range) 30
(12e62)
30
(16e53)
27
(18e45)
.001
NYHA class I (%) 70 74 47 .001
Type of heart
disease
.001
Congenital (%) 66 74 18
Valvular (%) 25 18 72
Other (%) 9 8 10
Prior cardiac
surgery (%)
54 59 22 .001
Drug use before
pregnancy (%)
28 26 37 .002
Nulliparous (%) 50 52 34 .001
Outcome
Maternal
Maternal
mortality (%)
1 0.6 3.9 .001
Maternal hospital
admission (%)
26 23 41 .001
Heart failure (%) 12 11 23 .001
Foetal
Apgar score
<7 (%)
10 8.7 17 .001
Preterm birth
<37 wk (%)
15 16 11 NS
Foetal death (%) 1.7 0.9 6.5 .001
Neonatal death (%) 0.6 0.6 0.5 NS
Birth weight (g) 3010 3027 2899 .004
NYHA, New York Heart Association. yNS, not significant
(P > .05).
a Reproduced with permission from Registry On Pregnancy
and Cardiac disease (ROPAC).7Introduction
In developed Western countries, heart disease in preg-
nancy (HDP) has an incidence of 0.2%e4% and is the most
frequent cause of maternal death.1e3 Cardiac conditions that
contribute to maternal death may present acutely and
catastrophically.2,3 Recognition of risk factors for these
conditions may predict complications and permit the
establishment of a plan to minimize or prevent
complications.3,4 Therefore, knowledge and experience in
HDP are important so that health-care providers can
deliver proper counselling and treatment.3,5
European HDP experts have recognized the need for
better understanding of the relation between pregnancy and
heart disease. In 2007, they launched an international
Registry On Pregnancy and Cardiac Disease (ROPAC)
under the umbrella of the European Society of Cardiology
(ESC).6,7 The registry enrolled 1321 women who had
structural heart disease. Although most of the women
were from developed countries (1136 women [86%]), some
were from developing countries (185 women [14%]).7
Significant differences between developed and developing
countries were observed in this registry (Table 1).7 These
differences reflect the level of medical care in developed
and developing countries. In developed countries, optimal
care and preconception counselling were available in all
centres, but few women in developing countries who had
heart disease were assessed and appropriately counselled
before conception.7e9
The purpose of this article is to explore the current status
of heart disease in pregnancy in KSA and compare it to the
current international situation with the goal of designing and
describing the Registry Of Saudi Heart Disease And Preg-
nancy (ROSHDAP).
Materials and Methods
Searching the ProQuest MEDLINE search engine
(MEDLINE is a bibliographic database produced by the
U.S. National Library of Medicine) using cardiovascular
disease in pregnancy as a keyword phrase, an extensive
literature review about heart disease in pregnancy was per-
formed (see Figure 1). The search involved English-language
peer review articles from 1945 through 2016. When the
search was limited to Saudi publications about heart disease
and pregnancy, only 10 relevant articles were found: 4
clinical retrospective studies, 4 case reports and 2 review
articles (see Table 2). To enrich the search about
cardiovascular disease in KSA regardless of pregnancy,
multiple attempts with different logical entries were
performed and 253 peer-reviewed Saudi articles wereidentified. Nevertheless, to obtain recent data about heart
disease in pregnancy, the search for worldwide publications
was narrowed toward more recently published papers be-
tween 2010 and 2016. After excluding case reports and re-
view articles, 861 studies were identified and manually
screened for close relevancy to HDP. In addition, 253 Saudi
publications about cardiovascular disease were manually
screened. Ultimately, 31 closely relevant articles were chosen
to support this article.Results
Rationale for ROSHDAP
In developing countries, RHD is the most common cause
of HDP (72%), increases the risk of pregnancy, and is a
major non-obstetric cause of maternal death.7,8,10,12
Although RHD might still be a major problem in KSA,
current data about RHD are not available.
The ROPAC study showed that congenital heart disease
(CHD) is the most frequent cause of HDP in developed
countries (74%) and the second-most-frequent cause of HDP
in developing countries (18%). The two factors of the KSA’s
Figure 1: Flow chart showing ProQuest MEDLINE search for CVD, cardiovascular disease; KSA.
Heart disease during pregnancy 407high birth rate (22 births per 1000 population, twice that of
Europe) and the high prevalence of consanguinity (57.7%)
might enhance the prevalence of CHD in KSA.12,13
Consanguineous marriages have been linked to congenital
heart disease in children of marriages between first cousins
in KSA.14 Furthermore, the potential for girls who have
complex congenital heart disease to reach reproductive age
in good health and conceive has markedly improved in
KSA because of advances in cardiac paediatric surgery and
neonatal medicine. However, no published data are
available about congenital heart disease in pregnant
women in KSA.
Cardiomyopathies (dilated, restrictive, and hypertrophic)
are a group of myocardial disorders characterized by struc-
tural and functional abnormalities of the ventricular
myocardium that cannot be explained by coronary artery
disease or abnormal loading conditions.15 In the ROPAC
study, cardiomyopathy was responsible for 7% of
HDP.7,16,17 Peripartum cardiomyopathy (PPCM) is a form
of dilated cardiomyopathy related to pregnancy. Recently, a
worldwide registry of PPCM has been launched for a better
understanding of epidemiology, clinical characteristics and
outcomes for inpatients and outpatients with PPCM, the
diagnostic and therapeutic processes applied and their
impact on outcomes.18 There is only a limited amount of
published data about cardiomyopathy in KSA.18
Although coronary artery disease (CAD) was reported as
a major contributor to maternal mortality in the British
enquiry ‘SavingMothers Lives,’ it was rarely noted as a cause
of structural heart disease in pregnancy in the ROPAC
study.19,7 In a relatively old (1995e2000) Saudi
epidemiological study about CAD, the prevalence of CAD
among reproductive-age women (30e39 years) was 3.9%.20
The prevalence of CAD might have increased recently
because of increasing CAD risk factors such as
hypertension, diabetes, smoking, and obesity in KSA.21,22
Overall, the published data about HDP in KSA are mini-
mal and relatively old.23e26 In addition, the level of medical
services in KSA is variable and includes a mixture offeatures observed in developed and developing countries.
This variability in medical care can affect the epidemiology
and outcomes of HDP. Therefore, a ROSHDAP study of
women with HDP is necessary to characterize their
problems, develop solutions, and generate future plans.
Proposed objectives of ROSHDAP
1. To determine of the magnitude of HDP in KSA,
including the following:
1.1. The incidence of HDP in participating centres and
throughout KSA.
1.2. Maternal and foetal morbidity and mortality during
and 6 months after pregnancy.
1.3. The frequency of utilization of costly medical re-
sources in KSA, including the following:
 Hospital admissions during pregnancy and within
6 months after delivery (mothers and neonates).
 Invasive cardiac interventions such as cardiac
surgery, balloon valvuloplasty, percutaneous
valve implant, and coronary intervention.
 Advanced foetal interventions.
 Caesarean deliveries.
 Epidural anaesthesia.
 Medication used before and during pregnancy.2. To assess obstacles to achieving safe medical care and to
compare regional differences in KSA.
3. To document the frequency and type of heart dis-
easedincluding RHD, congenital heart disease, cardio-
myopathy, and CADdamong pregnant women in KSA.
4. To determine the incidence of consanguinity in women
who have HDP in KSA.
5. To document the mode of birth in KSA in pregnant
women with heart disease.
6. To determine the incidence of congenital heart disease in
the neonates of Saudi women who have HDP.
7. To assess the effects of pregnancy on cardiac function
during and 6 months after pregnancy, as determined by
maternal echocardiography.
Table 2: Available Saudi publications about HDP.*
Serial
number
Topic Number of
pts with HDP
Study type Year of
publication
First author Journal
1 CHD** in pregnancy 1 Case report 2015 Elsherif,
Zeinelabdien
BMJ Case Rep.
2 IHD in pregnancy 1 Review article 2012 Bondagji,
Nabeel S.
Saudi Heart Assoc
3 Bioprosthetic valves in pregnancy 85 Retrospective
Study
2005 El, Shaer Fayez J. Heart Valve Dis.
4 Peripartum cardiomyopathy. e Review article 2003 Al-Shamiri,
Mostafa Q.
Saudi Med. J.
5 Pregnancy and valvular heart disease. 166 Retrospective
Study
2003 Faiz, Shakeel A. Saudi Med. J.
6 The nineteenth pregnancy in a patient
with cor- pulmonale
1 Case report 2003 Al-Mobeireek,
Abdullah F.
Acta Obstet.
Gynecol. Scand.
7 Mitral balloon valvotomy in pregnancy 23 Retrospective
Study
2001 Fawzy, M. E. J. Heart Valve Dis.
8 Anticoagulation for mechanical valve in
pregnancy
1 Case report 2000 Berndt, N. J. Heart Valve Dis
9 Pregnancy complicated by cardiac disease 229 Retrospective
Study
2000 Rahman, J. J. Obstet. Gynaecol.
10 Percutaneous mitral balloon valvotomy
in pregnancy
1 Case report 1991 Ribeiro, P. A. Rev. Port. Cardiol.
HDP*, Heart disease in pregnancy. CHD**, Congenital Heart Disease. IHD , Ischemic Heart Disease. BMJ , British Medical Journal.
F.O. Alatawi4088. To assess foetal anomalies, as determined by foetal
echocardiography.
9. To study the results and frequency of complications from
interventions performed during pregnancy.
10. To examine the World Health Organization (WHO) risk
score and outcomes in our population.27Figure 2: Schematic representation of the phases for the RegisProposed study design and population of ROSHDAP
The ROSHDAP study will be a prospective, multicentre,
hospital-based nationwide registry program. It will be
executed in 5 phases (Figure 2): (1) initiation: writing a
proposal and applying for funding; (2) development
(estimated duration, 6 mo): contacting co-investigators,try of Saudi Heart Disease And Pregnancy (ROSHDAP).
Heart disease during pregnancy 409assigning coordinators to the participating centres,
establishing a steering committee, and developing the
database and Web portal; (3) prelude and pilot study
(with a duration of one year): launching the registry in 4
large provinces (Riyadh, Mekkah, Almadinah
Almunawwarah, and Eastern Provinces) and enrolling 300
pregnant women who have HDP to assess the feasibility
and logistics of generalizing the registry in existing settings
and to provide preliminary data to increase the nationwide
registry; (4) nationwide (with a duration of five years):
expanding the registry to involve more centres in KSA and
enrolling 3000 patients who have HDP; and (5)
conclusion: using the data to write a final report, publish
research papers about HDP, and prepare strategic
guidelines for health care systems.
Proposed eligibility criteria for ROSHDAP
All pregnant women who have heart disease and who are
evaluated at participating centres will be eligible for inclusion
in ROSHDAP. Patients who do not provide informed con-
sent will be excluded from ROSHDAP.
Proposed database and web portal for ROSHDAP:
technical details
A relational database management system will be con-
structed to develop a repository of every HDP case in
KSA. The database will be developed and stored using
cloud computing technology, a database server (SQL
Server, Microsoft, Redmond, WA, USA), and a software
framework (.NET, Microsoft). The participating centres
will be provided with protected database access for data
entry. The populated data will be accessed for statistical
analysis by authorized central coordinator office
investigators.
Data collection for ROSHDAP
The ROSHDAP database will store information about
maternal preconception counselling, antenatal follow-up,
foetal status, labour, postnatal maternal and neonatal
follow-up, and paternal data. Data will include clinical
information, laboratory test results, cardiac studies (elec-
trocardiography, echocardiography, and cardiotocog-
raphy), and treatment information (medications, hospital
admissions, and therapeutic procedures). The National
Identity Number (NIN) of each participating patient will
be used to avoid double counting during a single preg-
nancy. Neonatal follow-up data will be recorded with
maternal data.
Registry management for ROSHDAP
Each participating province will have a designated
ROSHDAP coordinator to facilitate the tasks of every centre
in the province and to coordinate with the central coordi-
nating office. The central coordinating office will have re-
sponsibility and authority for all registry data. A ROSHDAP
steering committee will be organized with investigators from
all participating centres; this committee will monitor theregistry and information stored in the database and will be
responsible for making policy about statistical analysis and
publishing the findings. Co-investigators at participating
centres will supervise data collection and recording to ensure
data integrity and authenticity. Standardized data collection
forms will be used to collect the data, which will be recorded
directly onto theWeb portal, attempting to minimize missing
variables. The co-investigators will have full access to their
data and will be updated periodically about other centres’
performance.Follow-up for ROSHDAP
Patients will undergo 3 follow-up visits: upon entry to the
registry, at delivery, and 6 months postpartum. An echo-
cardiogram will be performed for mothers during pregnancy
and at 6 months postpartum. Foetal ultrasound will be
performed between 18 and 22 weeks gestation and neonatal
echocardiography will be performed in the first 6 months
after birth. Assessment for outcomes will be performed at
follow-up. Standardized definitions will be used for
maternal, foetal, neonatal, and infant complications
(Tables 3 and 4). Deaths and causes of death will be
recorded. Morbidity will be recorded from a review of
hospital records for new symptoms, clinical findings,
investigations, treatment, and nonsurgical and surgical
intervention. Other necessary information will be obtained
by contacting treating physicians, patients, or patient
families. Audits of the collected data (including outcomes)
will be performed every 3 months.Ethical concerns of ROSHDAP
The registry must be approved by the ethical committee of
Taibah University. In addition, an agreement to participate
and release data will be obtained from the ethical committees
at all participating centres. All participating patients will be
informed about the registry and asked to complete a consent
form. Consent will be scanned and recorded electronically
with the patient data and strict confidentiality will be
observed.Statistical analysis for ROSHDAP
The stored data will be accessed and formatted to enable
statistical analysis. Data analyses will be performed with
statistical software (SPSS, version 17.0, SPSS Inc., Chicago,
IL, USA). Descriptive data will be summarized as the mean
and standard deviations for continuous variables and as
percentages for categorical variables. The incidence of all
outcome events will be presented as frequency using
KaplaneMeier method. The association of risk factors with
pregnancy outcomes will be evaluated using Cox’s propor-
tional hazard regression. Comparisons of variables between
provinces will be performed using either a t test or a chi-
square test. Statistical significance will be defined by
P  .05 (2-sided test) unless otherwise noted.
Table 4: Foetal, newborn, and infant complications from reg-
istry entry until 6 months after delivery.
Complication Diagnostic Criteria
Abortion Spontaneous expulsion of the foetus
during the first 12 weeks of gestation
Foetal death Death after 22 weeks of gestation or
foetal weight >500 g
Neonatal death Death of a baby within the first
28 days after birth
Infant death Death of an infant from >28 days to
1 year after birth
Intrauterine
growth restriction
Foetal weight estimation and/or birth
weight <10th percentile
Low Apgar score Score <7 at 1 and 5 min
Congenital heart
disease
Documented by echocardiography
Congenital anomalies World Health Organization definition:
structural or functional anomalies
(such as metabolic disorders) that
occur during intrauterine life and can
be identified prenatally, at birth, or
later in life
Neonatal bradycardia Heart rate <100 beats per minute
Table 3: Maternal complications at any time from registry
entry until 6 months after delivery.
Complication Diagnostic Criteria
General
Death Any cause
Congestive heart failure Based on Framingham criteria29
Acute coronary syndrome ACC/AHA criteriaa,31
Stroke Sudden occurrence of
neurologic deficit for 24 h
Transient ischemic attack Neurologic deficit for <24 h
Peripheral embolism Evidence of end-organ
ischemia (such as ischemic
limb pain or gangrene)
New-onset major arrhythmia
(atrial or ventricular)
Electrocardiographic evidence
Infective endocarditis Modified Duke criteria30
Cardiac surgery Any cardiac surgical
intervention
Percutaneous intervention Catheter-based intervention
for any part of cardiovascular
system
Prosthetic valve thrombosis Confirmed by echocardiography
and/or cinefluoroscopy
Hospital admission 1 day
Intra- or extracardiac
vascular conduit
thrombosis
Confirmed by ultrasonography
and/or any other imaging
modality
Major bleeding Bleeding that causes reduction
of haemoglobin by 1 g or
requires blood transfusion
Obstetric
Pregnancy-induced
hypertension
Blood pressure >140/90 mm Hg
documented after 20 weeks of
gestation
Preeclampsia Pregnancy-induced hypertension
criteria and >0.3 g proteinuria
in 24-h urine
Eclampsia Preeclampsia and seizures
Premature rupture of
membranes
Membrane rupture before
onset of uterine contractions
Antepartum haemorrhage Vaginal bleeding during the
second half of pregnancy
(after 20 weeks of gestation)
Assisted delivery Suction device and/or forceps
Caesarean delivery (1) Cardiac indication,
(2) Obstetric indication
Postpartum haemorrhage Vaginal delivery, haemorrhage
>500 mL, caesarean delivery
>1000 ml, or requiring
transfusion
a ACA/AHA, American College of Cardiology/American
Heart Association.31
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Recently, research in the field of heart disease during
pregnancy has attracted more attention: clinical studies,
registries, and guideline articles are emerging from all over
the world, especially from Europe and the USA.2e
8,11,16,17,19,27,28 That notwithstanding, the situation in KSA
is unfortunately different: Saudi publications about HDP
are old and few in number.23e26 In 2000, Jessica et al.
published KSA’s first HDP study, which was a single-centre experience and reported old data of 229 patients
with HDP delivered between 1982 and 1997.23 They
described a 0.6% incidence of HDP, with rheumatic fever
the most frequent aetiology (75.9%) followed by congenital
heart disease (17.9%). The study reflects a typical situation
of HDP in developing countries at that time. The second
Saudi study, published in 2001, described the success and
safety of balloon valvoplasty in 23 pregnant women with
severe mitral valve stenosis. In the third Saudi study,
published in 2003 and reporting on 166 patients with HDP,
the description of cardiac lesions was superficial and
ambiguous.25 In the most recent Saudi study about HDP,
published in 2005, El-shaer et al. conclude that pregnancy
did not accelerate the degeneration of bioprosthetic valves in
49 patients who had repeated pregnancies and followed up to
maximum of 18 years.26
Considering the absence of contemporary data about
HDP in KSA, the research in this field is becoming both
urgent and obligatory. Thus, this article’s primary goal is to
activate this task by constructing the ROSHDAP study,
which will create an extensive database concerning HDP in
KSA. The pilot study should be encouraging because it in-
volves tertiary hospitals in KSA with expertise in this field.
The data that will be collected will include detailed infor-
mation about pre-pregnancy counselling, consanguinity,
psychosocial factors, the aetiology of HDP, clinical factors,
laboratory issues, electrography, echocardiography, thera-
peutic interventions, mode of delivery, complications, and
foetal and maternal outcome of pregnancy and the first 6
months post natal. Thus, we will be able to calculate the
current incidence of HDP in KSA, identify the aetiology of
HDP, obtain detailed information about consanguinity,
conduct preconception counselling and identify risks of
foetal and maternal complications.
We expect to identify multiple risks of maternal and foetal
complications; these risks will be compared to previously
Heart disease during pregnancy 411reported risks in developed and developing countries.5,7,27
An attempt to build new risk scores and compare them to
previously validated risk scores, such as that of the WHO,
will be performed.5,6,28 The ROSHDAP study will
document the current level of health care provision to
women with HDP in KSA and data for comparison among
KSA regions will be available. This approach will create
opportunities to correct and rectify health care system,
services and plans for this group of patients. Considering
the absence of contemporary data about HDP in KSA, the
research in this field is becoming an urgent and obligatory
task.
Conclusion
Recent research about HDP in KSA is unavailable. The
suggested ROSHDAP study in this article will represent a
substantial opportunity to collect contemporary data on
HDP in KSA that will aid in developing management
guidelines, research programs, and health strategies, even-
tually improving HDP care.
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